Quantbot Technologies LP Buys 92,273 Shares of DexCom, Inc. $DXCM

Quantbot Technologies LP lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 2,255.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 96,364 shares of the medical device company’s stock after purchasing an additional 92,273 shares during the quarter. Quantbot Technologies LP’s holdings in DexCom were worth $6,484,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of DXCM. Vanguard Group Inc. lifted its position in DexCom by 2.3% in the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock worth $3,327,897,000 after buying an additional 1,133,638 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of DexCom by 3.4% in the second quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after acquiring an additional 358,617 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of DexCom by 106.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock worth $576,610,000 after acquiring an additional 3,410,858 shares during the last quarter. Norges Bank bought a new stake in shares of DexCom in the 2nd quarter worth about $453,279,000. Finally, Groupama Asset Managment boosted its stake in shares of DexCom by 79,043.1% during the 2nd quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company’s stock worth $350,601,000 after purchasing an additional 4,011,438 shares during the period. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on DXCM shares. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 16th. BTIG Research reiterated a “buy” rating and issued a $85.00 price target on shares of DexCom in a report on Wednesday. UBS Group dropped their price objective on DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a report on Monday, November 3rd. Canaccord Genuity Group set a $95.00 price objective on DexCom and gave the company a “buy” rating in a research report on Friday, February 13th. Finally, Wells Fargo & Company reduced their target price on DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $85.18.

DexCom Stock Performance

DXCM stock opened at $73.43 on Friday. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The business has a 50-day moving average price of $70.24 and a 200 day moving average price of $69.15. The company has a market capitalization of $28.26 billion, a P/E ratio of 34.97, a PEG ratio of 1.43 and a beta of 1.49. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The company had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same period in the prior year, the business earned $0.45 EPS. The firm’s quarterly revenue was up 13.1% on a year-over-year basis. As a group, equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.